Jarle von Hörsten
YOU?
Author Swipe
View article: Switch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational Study
Switch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational Study Open
SCIg is an effective alternative maintenance treatment for patients with CIDP and MMN who have previously responded to IVIg. Switching to an equivalent weekly dose of SCIg as a replacement for monthly IVIg is both feasible and effective in…
View article: Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions
Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions Open
Background: IgPro20 is the first approved subcutaneous immunoglobulin (SCIg) preparation for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Two different doses of the SCIg preparation were investig…